cjc 1295 for anti aging: Frequently asked questions

Growth hormone's anabolic effects are conditional on adequate protein intake (minimum 1.6 g/kg daily), resistance training stimulus, and caloric sufficiency. IGF-1 elevation alone doesn't drive hypertrophy. It signals the permissive hormonal environment for muscle protein synthesis, but the mechanical and nutritional inputs must be present. If IGF-1 is 250+ ng/mL and lean mass isn't increasing, the limiting factor is training volume or dietary protein, not the peptide.

The most studied combination is CJC-1295 (sustained baseline GH elevation) with ipamorelin (acute GH pulse amplification) dosed 1–2 hours before bed. This targets both chronic tissue maintenance and sleep-phase GH secretion. Avoid combining with exogenous GH. The mechanisms overlap and you'll suppress endogenous production. Real Peptides' CJC-1295 Ipamorelin blend is formulated at a 1:1 ratio specifically for this protocol.

Verify you're using the DAC version and dosing at 30–60 mcg/kg weekly. If you're dosing modified GRF(1-29) at the same frequency, plasma levels clear within hours and IGF-1 won't elevate. The second most common cause is reconstitution error. CJC-1295 DAC requires bacteriostatic water and refrigeration at 2–8°C post-mixing; temperature excursions above 8°C denature the peptide structure irreversibly.

Discard it. CJC-1295 stored at room temperature (20–25°C) for 12–24 hours loses 25–35% of its receptor-binding affinity due to oxidative degradation of methionine residues and partial denaturation of the DAC modification. The peptide may still appear clear and colorless, but potency is compromised in ways home testing cannot detect. Refrigeration at 2–8°C is non-negotiable for reconstituted peptides. A single temperature excursion renders the vial unreliable for the remainder of the protocol.

A plateau at 8–10 weeks typically indicates one of two things: either the protocol has reached the ceiling of what twice-weekly dosing can achieve with your current secretagogue pairing, or somatostatin feedback is limiting further GH pulse amplification. Before increasing dose frequency, verify injection timing. Are you dosing 30–45 minutes before sleep consistently? Pulses triggered during waking hours produce 30–40% lower IGF-1 response than nocturnal dosing. If timing is correct and you've been using GHRP-2 or GHRP-6, consider switching to ipamorelin, which has lower feedback inhibition on somatostatin tone and allows more sustained GH elevation over 12+ week protocols.

You'll see minimal GH elevation because CJC-1295 amplifies pulses. It doesn't initiate them. Without a GHRP or ghrelin mimetic to trigger the pulse, CJC-1295 is amplifying baseline GH secretion, which in adults over 30 occurs only 6–8 times daily and at progressively lower amplitude. Clinical data shows CJC-1295 monotherapy produces IGF-1 elevations 40–50% lower than combination protocols. If you're running CJC-1295 alone, add ipamorelin at 200–300mcg per injection to initiate the pulse CJC-1295 will then extend and amplify.